$TCMD
TACTILE SYSTEMS TECHNOLOGY INC

2022 Q1 Form 10-Q Financial Statement

#000155837022006649 Filed on May 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $47.98M $42.77M
YoY Change 12.17% -2.07%
Cost Of Revenue $14.12M $12.54M
YoY Change 12.55% -0.48%
Gross Profit $33.86M $30.23M
YoY Change 12.01% -2.71%
Gross Profit Margin 70.58% 70.68%
Selling, General & Admin $40.15M $32.99M
YoY Change 21.68% -2.5%
% of Gross Profit 118.56% 109.14%
Research & Development $1.520M $1.270M
YoY Change 19.69% -24.58%
% of Gross Profit 4.49% 4.2%
Depreciation & Amortization $1.507M $652.0K
YoY Change 131.13% -10.68%
% of Gross Profit 4.45% 2.16%
Operating Expenses $48.76M $34.31M
YoY Change 42.11% -3.41%
Operating Profit -$14.90M -$4.084M
YoY Change 264.86% -8.25%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$456.0K -$10.00K
YoY Change 4460.0% -103.76%
Pretax Income -$15.36M -$4.094M
YoY Change 275.11% -2.17%
Income Tax $200.0K -$1.800M
% Of Pretax Income
Net Earnings -$15.57M -$2.266M
YoY Change 587.03% 73.37%
Net Earnings / Revenue -32.45% -5.3%
Basic Earnings Per Share -$0.78 -$0.12
Diluted Earnings Per Share -$0.78 -$0.12
COMMON SHARES
Basic Shares Outstanding 19.90M 19.55M
Diluted Shares Outstanding 19.90M 19.55M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.46M $46.93M
YoY Change -28.7% 4.66%
Cash & Equivalents $21.15M $46.93M
Short-Term Investments $12.31M $0.00
Other Short-Term Assets $4.374M $2.200M
YoY Change 98.82% 10.0%
Inventory $19.48M $22.04M
Prepaid Expenses
Receivables $45.93M $40.04M
Other Receivables $0.00 $0.00
Total Short-Term Assets $103.2M $122.5M
YoY Change -15.72% 9.06%
LONG-TERM ASSETS
Property, Plant & Equipment $6.330M $6.746M
YoY Change -6.17% -8.02%
Goodwill $31.06M
YoY Change
Intangibles $53.17M $1.683M
YoY Change 3059.18% -67.67%
Long-Term Investments
YoY Change
Other Assets $2.321M $2.030M
YoY Change 14.33% -9.33%
Total Long-Term Assets $129.8M $52.78M
YoY Change 145.89% 22.17%
TOTAL ASSETS
Total Short-Term Assets $103.2M $122.5M
Total Long-Term Assets $129.8M $52.78M
Total Assets $233.0M $175.3M
YoY Change 32.94% 12.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.200M $9.352M
YoY Change -33.7% 7.01%
Accrued Expenses $5.673M $3.227M
YoY Change 75.8% -35.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.964M
YoY Change
Total Short-Term Liabilities $40.27M $27.99M
YoY Change 43.91% 13.2%
LONG-TERM LIABILITIES
Long-Term Debt $48.08M $0.00
YoY Change
Other Long-Term Liabilities $29.54M $22.20M
YoY Change 33.05% 24.72%
Total Long-Term Liabilities $77.76M $22.17M
YoY Change 250.76% 24.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.27M $27.99M
Total Long-Term Liabilities $77.76M $22.17M
Total Liabilities $118.0M $50.15M
YoY Change 135.34% 18.07%
SHAREHOLDERS EQUITY
Retained Earnings -$7.323M $17.79M
YoY Change -141.16% -8.15%
Common Stock $20.00K $20.00K
YoY Change 0.0% 5.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $115.0M $125.1M
YoY Change
Total Liabilities & Shareholders Equity $233.0M $175.3M
YoY Change 32.94% 12.7%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$15.57M -$2.266M
YoY Change 587.03% 73.37%
Depreciation, Depletion And Amortization $1.507M $652.0K
YoY Change 131.13% -10.68%
Cash From Operating Activities -$3.206M -$800.0K
YoY Change 300.75% -188.01%
INVESTING ACTIVITIES
Capital Expenditures $131.0K $249.0K
YoY Change -47.39% -30.45%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$175.0K -$311.0K
YoY Change -43.73% -103.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.698M 181.0K
YoY Change -2143.09% -118.32%
NET CHANGE
Cash From Operating Activities -3.206M -800.0K
Cash From Investing Activities -175.0K -311.0K
Cash From Financing Activities -3.698M 181.0K
Net Change In Cash -7.079M -930.0K
YoY Change 661.18% -109.76%
FREE CASH FLOW
Cash From Operating Activities -$3.206M -$800.0K
Capital Expenditures $131.0K $249.0K
Free Cash Flow -$3.337M -$1.049M
YoY Change 218.11% -290.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2022Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2022Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001027838
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19939843
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19877786
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-37799
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
26000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5022000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
16000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2504000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2506000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4275000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3305000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5023000
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Tactile Systems Technology, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3701 Wayzata Blvd, Suite 300
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1801204
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55416
CY2022Q1 dei City Area Code
CityAreaCode
612
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
355-5100
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2022Q1 dei Trading Symbol
TradingSymbol
TCMD
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19939296
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21150000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28229000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
45927000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49478000
CY2022Q1 us-gaap Net Investment In Lease
NetInvestmentInLease
12307000
CY2021Q4 us-gaap Net Investment In Lease
NetInvestmentInLease
12482000
CY2022Q1 us-gaap Inventory Net
InventoryNet
19479000
CY2021Q4 us-gaap Inventory Net
InventoryNet
19217000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4374000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4141000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
103237000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
113547000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6330000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6750000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23315000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23984000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53169000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
54081000
CY2022Q1 us-gaap Goodwill
Goodwill
31063000
CY2021Q4 us-gaap Goodwill
Goodwill
31063000
CY2022Q1 tcmd Medicare Accounts Receivable Non Current
MedicareAccountsReceivableNonCurrent
13577000
CY2021Q4 tcmd Medicare Accounts Receivable Non Current
MedicareAccountsReceivableNonCurrent
12847000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2321000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1998000
CY2022Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
129775000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
130723000
CY2022Q1 us-gaap Assets
Assets
233012000
CY2021Q4 us-gaap Assets
Assets
244270000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6200000
CY2022Q1 us-gaap Notes Payable Current
NotesPayableCurrent
2964000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2960000
CY2022Q1 tcmd Earn Out Current
EarnOutCurrent
9150000
CY2021Q4 tcmd Earn Out Current
EarnOutCurrent
3250000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9481000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12139000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5673000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5262000
CY2022Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
23199000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
40273000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34461000
CY2022Q1 us-gaap Line Of Credit
LineOfCredit
24878000
CY2021Q4 us-gaap Line Of Credit
LineOfCredit
24857000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
26933000
CY2022Q1 tcmd Earn Out Non Current
EarnOutNonCurrent
3500000
CY2021Q4 tcmd Earn Out Non Current
EarnOutNonCurrent
2950000
CY2022Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
2997000
CY2021Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3108000
CY2022Q1 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
298000
CY2021Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
348000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22742000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23354000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
147000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
32000
CY2022Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
77761000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
81582000
CY2022Q1 us-gaap Liabilities
Liabilities
118034000
CY2021Q4 us-gaap Liabilities
Liabilities
116043000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19939843
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19877786
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
122281000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
119962000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7323000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
8245000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
114978000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
128227000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233012000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
244270000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47978000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42772000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
14116000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
12542000
CY2022Q1 us-gaap Gross Profit
GrossProfit
33862000
CY2021Q1 us-gaap Gross Profit
GrossProfit
30230000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
23930000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18785000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1520000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1270000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16217000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3479000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14209000
CY2022Q1 tcmd Amortization Of Intangible Assets And Earn Outs
AmortizationOfIntangibleAssetsAndEarnOuts
7096000
CY2021Q1 tcmd Amortization Of Intangible Assets And Earn Outs
AmortizationOfIntangibleAssetsAndEarnOuts
50000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
48763000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
34314000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14901000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4084000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-456000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15357000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4094000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
211000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1828000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15568000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2266000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.78
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.12
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.78
CY2021Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.12
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19898502
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19545558
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19898502
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19545558
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
128227000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2228000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15568000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
114978000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
124750000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2457000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1296000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-1115000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2266000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
125122000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-15568000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-2266000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1507000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
652000
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-115000
CY2021Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1828000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2228000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2457000
CY2022Q1 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-6450000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3551000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3806000
CY2022Q1 tcmd Increase Decrease In Net Investment In Lease
IncreaseDecreaseInNetInvestmentInLease
-175000
CY2021Q1 tcmd Increase Decrease In Net Investment In Lease
IncreaseDecreaseInNetInvestmentInLease
546000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
262000
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
40000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
556000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-447000
CY2022Q1 tcmd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-55000
CY2021Q1 tcmd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-49000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
730000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
1294000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1177000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2658000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3041000
CY2022Q1 tcmd Increase Decrease In Other Accrued Liabilities And Income Taxes Payable
IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
1350000
CY2021Q1 tcmd Increase Decrease In Other Accrued Liabilities And Income Taxes Payable
IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
-779000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3206000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-800000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
131000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
249000
CY2022Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
44000
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
62000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-175000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-311000
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3750000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
39000
CY2021Q1 tcmd Payment Of Taxes For Net Share Settlement Of Restricted Stock Units
PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits
1115000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
91000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1296000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3698000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
181000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7079000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-930000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28229000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47855000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21150000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46925000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
413000
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
12000
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
13000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
8000
CY2021Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
133000
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Note 1. Nature of Business and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Tactile Systems Technology, Inc. (“we,” “us,” and “our”)  manufactures and distributes medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition.</span> <span style="font-family:'Arial','Helvetica','sans-serif';">We provide our Flexitouch® and Entre™ systems through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">On September 8, 2021, we acquired the assets of the AffloVest airway clearance business (“AffloVest Acquisition”) from International Biophysics Corporation (“IBC”), a privately-held company which developed and manufactures AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. We sell this device through home medical equipment and durable medical equipment providers throughout the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in our reincorporation as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as “Tactile Medical”.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. </span><span style="font-family:'Arial','Helvetica','sans-serif';">Further, seasonality trends have been, and may continue to be, significantly different than historical trends as a result of the COVID-19 pandemic and related impacts</span><span style="font-family:'Arial','Helvetica','sans-serif';">.</span></p>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;"><span style="color:#2b2c2b;font-family:'Arial','Helvetica','sans-serif';">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
CY2021Q3 tcmd Goodwill Amortization Period For Tax Purposes
GoodwillAmortizationPeriodForTaxPurposes
P15Y
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53500000
CY2021Q3 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y3M18D
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9433000
CY2021Q4 us-gaap Inventory Net
InventoryNet
19217000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45939000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2855000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43084000
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
56024000
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2855000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
8242000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
10046000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
10975000
CY2022Q1 us-gaap Inventory Net
InventoryNet
19479000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53169000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45916000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1900000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44016000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
55981000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1900000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
54081000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2867000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3793000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3771000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3682000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3617000
CY2022Q1 tcmd Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
25354000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
43084000
CY2022Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1998000
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1851000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1248000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1371000
CY2022Q1 tcmd Accrued Travel And Entertainment Current
AccruedTravelAndEntertainmentCurrent
752000
CY2021Q4 tcmd Accrued Travel And Entertainment Current
AccruedTravelAndEntertainmentCurrent
661000
CY2022Q1 tcmd In Transit Inventory Accrued Expense
InTransitInventoryAccruedExpense
611000
CY2021Q4 tcmd In Transit Inventory Accrued Expense
InTransitInventoryAccruedExpense
416000
CY2022Q1 tcmd Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
122000
CY2021Q4 tcmd Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
113000
CY2022Q1 tcmd Accrued Sales And Use Tax
AccruedSalesAndUseTax
71000
CY2021Q4 tcmd Accrued Sales And Use Tax
AccruedSalesAndUseTax
106000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
871000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
744000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5673000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5262000
CY2021Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4959000
CY2020Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4841000
CY2022Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
643000
CY2021Q1 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
612000
CY2022Q1 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
607000
CY2021Q1 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
584000
CY2022Q1 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4995000
CY2021Q1 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4869000
CY2022Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1998000
CY2021Q1 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1610000
CY2022Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
2997000
CY2021Q1 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3259000
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4995000
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4869000
CY2021Q3 tcmd Line Of Credit Threshold Contingent Increase In Borrowing Capacity
LineOfCreditThresholdContingentIncreaseInBorrowingCapacity
25000000.0
CY2021Q3 tcmd Credit Agreement Total Aggregate Principal Amount
CreditAgreementTotalAggregatePrincipalAmount
80000000.0
CY2021Q3 us-gaap Line Of Credit
LineOfCredit
25000000.0
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23315000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23984000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2504000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2506000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22742000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23354000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
25246000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
25860000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
918000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
789000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
41000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
124000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2658000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3425000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3415000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3516000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3615000
CY2022Q1 tcmd Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
13249000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
29878000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4632000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
25246000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2504000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22742000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1000000.0
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
800000
CY2022Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
38800000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2200000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2500000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2228000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2457000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47978000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42772000
CY2022Q1 tcmd Percentage Of Revenue
PercentageOfRevenue
1
CY2021Q1 tcmd Percentage Of Revenue
PercentageOfRevenue
1
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47978000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42772000
CY2022Q1 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
6808000
CY2021Q1 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
6647000
CY2022Q1 us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
2036000
CY2021Q1 us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
1851000
CY2022Q1 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
4772000
CY2021Q1 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
4796000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.014
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.446
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1800000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15568000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2266000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19898502
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19545558
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19898502
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19545558
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.78
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1597884
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1406586
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
12700000
CY2022Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3500000

Files In Submission

Name View Source Status
0001558370-22-006649-index-headers.html Edgar Link pending
0001558370-22-006649-index.html Edgar Link pending
0001558370-22-006649.txt Edgar Link pending
0001558370-22-006649-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcmd-20220331.xsd Edgar Link pending
tcmd-20220331x10q.htm Edgar Link pending
tcmd-20220331x10q_htm.xml Edgar Link completed
tcmd-20220331xex31d1.htm Edgar Link pending
tcmd-20220331xex31d2.htm Edgar Link pending
tcmd-20220331xex32d1.htm Edgar Link pending
tcmd-20220331xex32d2.htm Edgar Link pending
tcmd-20220331_cal.xml Edgar Link unprocessable
tcmd-20220331_def.xml Edgar Link unprocessable
tcmd-20220331_lab.xml Edgar Link unprocessable
tcmd-20220331_pre.xml Edgar Link unprocessable